SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is facing intense downward pressure driven by a mix of broader SaaS sector volatility and aggressive short-selling as investors debate the impact of AI competition on its long-term moat. While the community remains deeply divided between those viewing the current price as a deep-value buying opportunity and those fearing further dilution from upcoming lockup expirations and insider sales.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a long-standing crypto joke that has evolved into an on-chain parody, drawing significant attention from community members who believe its deep history and meme status position it as a unique asset. Discussions are currently dominated by comparisons to Bitcoin's early days, debate over the project's legitimacy versus its satirical roots, and strong calls for community members to hold through volatility in hopes of long-term growth.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is currently at the center of a heated debate over whether AI disruption via tools like Anthropic represents a fatal structural threat to legacy SaaS providers or a temporary, sentiment-driven repricing opportunity. Community members remain deeply divided between short-sellers anticipating a permanent valuation collapse and bulls who argue that major software incumbents are oversold and fundamentally resilient, leading to high-volume institutional buying and significant volatility.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) is currently at the center of a heated debate between retail traders who view it as an unstoppable "money machine" fueled by insatiable AI infrastructure demand and skeptics pointing to extreme valuation premiums and potential technical divergences. While bullish participants highlight the sector's leadership role and resilient price action, a vocal cohort of bears remains focused on the potential for a sharp correction as they monitor key support levels and signs of overextension.

Maulcoin

Maulcoin is trending as its community aggressively rallies to regain market momentum and push the ticker back onto major trading platforms. Supporters are actively engaging in social media raids and liquidity-focused community building to drive visibility for what they describe as a long-term, anti-rug project.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management systems, as well as other tools, integrations, and native payment solutions. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot is facing intense selling pressure as investors grapple with concerns that generative AI and agentic platforms could disrupt traditional SaaS business models and drive down demand for seat-based licensing. While many analysts maintain buy ratings and emphasize the company's strong fundamentals, the stock is struggling to find a bottom as the market remains skeptical about the long-term impact of AI on the software sector's growth potential.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant momentum driven by massive whale accumulation, liquidation of short positions, and speculative anticipation of major corporate partnerships. While bulls are focused on the token's potential within its decentralized event ecosystem, the community remains divided between those expecting further breakout rallies and skeptics warning of a potential correction due to incoming supply releases.

Tidal Trust II - YieldMax Semiconductor Portfolio Option Income ETF

YieldMax Semiconductor Portfolio Option Income ETF

CHPY is generating significant buzz as a high-income ETF, with investors frequently highlighting its ability to sustain weekly distributions while showing relative stability in its net asset value compared to other single-stock YieldMax funds. The community is actively discussing the fund's heavy exposure to the semiconductor sector and debating whether its unique structure of owning underlying assets provides a more resilient path for long-term income generation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors react to its massive 25 billion dollar investment in Mississippi data centers, coupled with strong AWS AI momentum and reports of supply constraints for its custom AI chips. The community is actively debating the company's long-term potential as an AI infrastructure powerhouse while closely monitoring geopolitical risks and their impact on cloud operations in the Middle East.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is currently a battleground stock as investors weigh its fundamental strengths against market fears that agentic AI competition might displace its core automation business. While some investors see the stock as deeply undervalued given its cash position and role in enterprise workflows, others remain skeptical, leading to high short interest and intense community debate over whether the stock is a value trap or a coiled spring awaiting a breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 IDEAYA Biosciences to Announce Topline Results from Phase 2/3...

IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA)

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the target of some unusual options trading on Monday. Investors bought 24,287 call options on the stock. This represents an increase of 2,391% compared to the average volume of 975 call options...

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate...

Wedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA)

Wedbush reissued an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday...

37,595 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL bought a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 37,595 shares of the com...

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1% - Here's Why

IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 6.1% - What's Next...

IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA)

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the target of unusually large options trading on Monday. Investors purchased 9,704 put options on the stock. This is an increase of 1,197% compared to the typical daily volume of 748 put options...

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial IDEAYA Biosciences Upcoming Investor Relations Events and...

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Warranted - fundamentals justify the decline

Overdone - the market is overreacting

Too early to tell

Is the selloff in software stocks warranted or overdone?

Stocktwits

Stocktwits Polls

Traders are closely watching the upcoming topline Phase 2/3 trial results being released this Monday.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.99	--	--	N/A
Q4 '25	-$0.95	-$0.94	1.23%	BEAT
Q3 '25	-$0.83	$1.47	277.36%	BEAT
Q2 '25	-$0.78	-$0.88	-12.56%	MISSED
Q1 '25	-$0.66	-$0.82	-24.03%	MISSED

IDYA
Ideaya Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest IDYA News

IDYAIdeaya Biosciences Inc